
CLAIMS

1. Use of a compound of Formula (XIV):



Formula (XIV);

wherein:

R^1 is H or $C_{1\text{-}6}$alkyl;

R^2 is $C_{1\text{-}6}$alkyl;

R^3 is H or $C_{1\text{-}6}$alkyl;

R^4 and R^5 are independently selected from H and $C_{1\text{-}6}$alkyl;

each R^6 is independently selected from $C_{1\text{-}6}$alkyl, halogen, -CN, and $C_{1\text{-}6}$haloalkyl;

n is 0, 1, 2, 3, or 4; and





p is 0 or 1;


or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment of dyskinesia.


2. The use of claim 1, wherein n is 1 and R^6 is $-CF_3$.

3. The use of claim 1, wherein p is 0.

4. The use of claim 1, wherein the compound is selected from:



,

,

,

,



, and 

; or a pharmaceutically acceptable salt or solvate thereof.

5. The use of claim 1, wherein the compound is:



; or a pharmaceutically acceptable salt or solvate thereof.

6. The use of any one of claims 1 to 5, wherein the dyskinesia is levodopa-induced dyskinesia.